Role of the aryl hydrocarbon receptor (AhR) in lung inflammation

Celine A. Beamer; David M. Shepherd

doi:10.1007/s00281-013-0391-7

Role of the aryl hydrocarbon receptor (AhR) in lung inflammation

Celine A. Beamer
, David M. Shepherd

Research output: Contribution to journal › Review article › peer-review

78 Scopus citations

Abstract

Millions of individuals worldwide are afflicted with acute and chronic respiratory diseases, causing temporary and permanent disabilities and even death. Oftentimes, these diseases occur as a result of altered immune responses. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in the lungs through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. Finally, we address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.

Original language	English
Pages (from-to)	693-704
Number of pages	12
Journal	Seminars in Immunopathology
Volume	35
Issue number	6
DOIs	https://doi.org/10.1007/s00281-013-0391-7
State	Published - Nov 2013

Funding

This work is supported in part by National Institutes of Health grants R01 ES013784 (DMS) and R15 ES020993A (CAB). Also, the authors acknowledge the use of the CEHS Core Facilities at the University of Montana (supported by grant P20 RR017670), and generous support from Dr. Jacquie Harper and her research group at the Malaghan Institute of Medical Research in Wellington, New Zealand. The contents of this publication are solely the responsibility of the authors and do not necessarily reflect the official views of the National Institutes of Health.

Funder number
R01 ES013784, R15 ES020993A
P20RR017670
P20 RR017670

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aryl hydrocarbon receptor
Asthma
Chronic obstructive pulmonary disease
Inflammation
Lung
Silicosis

Access to Document

10.1007/s00281-013-0391-7

Cite this

@article{7c0ded1daea648f085215f491279b9ec,

title = "Role of the aryl hydrocarbon receptor (AhR) in lung inflammation",

abstract = "Millions of individuals worldwide are afflicted with acute and chronic respiratory diseases, causing temporary and permanent disabilities and even death. Oftentimes, these diseases occur as a result of altered immune responses. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in the lungs through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. Finally, we address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.",

keywords = "Aryl hydrocarbon receptor, Asthma, Chronic obstructive pulmonary disease, Inflammation, Lung, Silicosis",

author = "Beamer, \{Celine A.\} and Shepherd, \{David M.\}",

note = "Funding Information: This work is supported in part by National Institutes of Health grants R01 ES013784 (DMS) and R15 ES020993A (CAB). Also, the authors acknowledge the use of the CEHS Core Facilities at the University of Montana (supported by grant P20 RR017670), and generous support from Dr. Jacquie Harper and her research group at the Malaghan Institute of Medical Research in Wellington, New Zealand. The contents of this publication are solely the responsibility of the authors and do not necessarily reflect the official views of the National Institutes of Health. ",

year = "2013",

month = nov,

doi = "10.1007/s00281-013-0391-7",

language = "English",

volume = "35",

pages = "693--704",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

TY - JOUR

T1 - Role of the aryl hydrocarbon receptor (AhR) in lung inflammation

AU - Beamer, Celine A.

AU - Shepherd, David M.

N1 - Funding Information: This work is supported in part by National Institutes of Health grants R01 ES013784 (DMS) and R15 ES020993A (CAB). Also, the authors acknowledge the use of the CEHS Core Facilities at the University of Montana (supported by grant P20 RR017670), and generous support from Dr. Jacquie Harper and her research group at the Malaghan Institute of Medical Research in Wellington, New Zealand. The contents of this publication are solely the responsibility of the authors and do not necessarily reflect the official views of the National Institutes of Health.

PY - 2013/11

Y1 - 2013/11

N2 - Millions of individuals worldwide are afflicted with acute and chronic respiratory diseases, causing temporary and permanent disabilities and even death. Oftentimes, these diseases occur as a result of altered immune responses. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in the lungs through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. Finally, we address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.

AB - Millions of individuals worldwide are afflicted with acute and chronic respiratory diseases, causing temporary and permanent disabilities and even death. Oftentimes, these diseases occur as a result of altered immune responses. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in the lungs through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. Finally, we address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.

KW - Aryl hydrocarbon receptor

KW - Asthma

KW - Chronic obstructive pulmonary disease

KW - Inflammation

KW - Lung

KW - Silicosis

UR - https://www.scopus.com/pages/publications/84886089624

U2 - 10.1007/s00281-013-0391-7

DO - 10.1007/s00281-013-0391-7

M3 - Review article

C2 - 23963493

AN - SCOPUS:84886089624

SN - 1863-2297

VL - 35

SP - 693

EP - 704

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

IS - 6

ER -

Role of the aryl hydrocarbon receptor (AhR) in lung inflammation

Abstract

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this